Vericel's stock price dropped 5.24% during intraday trading on Friday, as investors reacted to the company's latest financial results and valuation metrics.
The biotech company reported a Q1 2026 basic EPS loss of US$0.12, which represents a return to loss-making territory after previously profitable quarters. This comes despite the company showing a profitable trailing 12-month period with US$21.5 million in net income.
Investors appear concerned about Vericel's valuation, with the stock trading at a P/E ratio of 83.4x - significantly higher than the US Biotechs industry average of 17.8x. Additionally, the discounted cash flow (DCF) fair value of US$8.53 sits well below the current share price, raising questions about whether the stock's valuation has become stretched.